Lv12
30 积分 2024-04-24 加入
OA01.05 Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: Additional Analysis and Extended Follow-up
1小时前
求助中
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
1天前
已完结
Perioperative Nivolumab in Resectable Lung Cancer
1天前
已完结
OA01.05 Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: Additional Analysis and Extended Follow-up
20天前
已关闭
PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816
21天前
已完结
EP.07C.11 Adjuvant Immunotherapy for Patients with Resectable NSCLC after Pathologic Complete Response
21天前
已关闭
Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma
21天前
已关闭
放射治疗通过NK细胞调控肿瘤微环境的研究进展
3个月前
已完结
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy
3个月前
已完结
Neoadjuvant chemotherapy and low dose immunotherapy in resectable non-small cell lung cancer – A multi-center retrospective cohort analysis
3个月前
已完结
皖公网安备34019202002308
